Meningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
|
|
- Nathan Quinn
- 6 years ago
- Views:
Transcription
1 1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/ investigative use of a commercial product/ device in my presentation. 3 Meningococcal Update Meningococcal Disease Incidence* Incidence Rate (cases per 100,000 population) 6 Male Female Age (years) *In California, Georgia, Maryland, Tennessee, Connecticut, Minnesota, and Oregon, Rosenstein NE, et al. J Infect Dis. 1999;180:
2 5 Serogroup Distribution in the US 6 Most Cases in Adolescents and Young Adults Are Potentially Vaccine-Preventable* Potentially Vaccine-Preventable % 62% Other C Number of Cases 41% % Y B 86% 70% 72% 36% < Age Group *Serogroup distribution by age group, United States, ; potentially vaccine-preventable was calculated assuming 100% efficacy using an A/C/Y/W-135 quadrivalent vaccine! 1. CDC. Active Bacterial Core Surveillance (ABCs) Report. Neisseria meningitidis ! Available at:. Meningococcal Disease Is Serious but Preventable in Adolescents and Young Adults 7 Maryland Residents Diagnosed With Invasive Meningococcal Disease, January 1, 1990 to December 31, 1999 All Ages n / Total < 15 Years n / Total Years n / Total Fatal Cases 40 / 294! (13.6%) 5 / 109! (4.6%) 16 / 71 (22.5%) Potentially Vaccine-Preventable* 193 / 257! (75.1%) 64 / 94! (68.1%) 53 / 64 (82.8%) *Serogroup information was not available for all fatal cases! P = 0.001, < 15 yrs vs yrs! P = 0.04, < 15 yrs vs yrs! 1. Harrison LH, et al. JAMA. 2001;286:694.! ACIP Recommendations for Use of Meningococcal Vaccines Update MMWR, March 22, 2013;62(RR No. 2)! In 2007 ACIP recommended vaccination for all adolescents aged years and vaccination of children aged 2-10 years at increased risk of meningococcal infection! In 2009 ACIP recommended booster dose for persons who remained at increased risk! In 2010 ACIP recommended a booster dose at age 16 years for adolescents 8
3 Vaccination Recommended 9 Persons aged 11 through 18 years! Persons aged 2 months who are at increased risk! Complement deficiencies (C5-C9, properidin, factor H, factor D)! Anatomic or functional asplenia! Persons aged 9 months traveling to, or being a resident of, countries in which meningococcal disease in hyperendemic or epidemic, particularly if contact with the local population will be prolonged! Special populations such as unvaccinated or incompletely vaccinated first-year college students living in residence halls, military recruits, or microbiologists routinely working with Neisseria meningitidis! Vaccination of persons in at-risk groups (generally age <30 years) to control outbreaks Rationale for Adolescent Booster Dose 10 Goal of the 2005 ACIP recommendation was to protect persons aged 16 through 21 years! Vaccination recommended at age 11 or 12 years! more persons have preventive-care visits at age 11 or 12 years rather than at age 14 or 15 years! strengthen the pre-adolescent vaccination platform! vaccine was expected to protect adolescents through the entire period of increased risk Rationale for Booster Dose 11 Incidence for serogroups C and Y are at historic lows! However, the peak in disease among persons aged 18 years has persisted! From to , the estimated annual number of cases of serogroups C and Y meningococcal disease decreased 75% among persons aged years and only 27% among persons aged years! Estimated 53.6% of adolescents aged years had received a dose of meningococcal vaccine Rationale for Booster Dose Vaccine effectiveness (VE) wanes! Case control study by the CDC begun Jan 2006! As of October 1, 2010, 108 case-patients and 158 controls enrolled! Vaccinated <1 year earlier, VE 95% (95th percentile CI %)! Vaccinated 1 year earlier, VE 78% (95th percentile CI 29-93%)! Vaccinated 2-5 years earlier, VE 58% (95th percentile CI %) 12
4 Rationale for Booster Dose 13 Serologic data are consistent with waning immunity! Three characteristics of conjugate vaccines important for long-term protection! circulating antibody! memory response! herd immunity Rationale for Booster Dose 14 Memory response might not be rapid enough to protect against meningococcal disease! After initial priming with a serogroup C meningococcal conjugate vaccine, a memory response was not measurable until 5-7 days later! Incubation period for meningococcal disease is usually less than 3 days! Immunization coverage not at levels to provide evidence for herd immunity! Therefore, it is felt circulating bactericidal is critical for protection Rationale for Booster Dose 15 Five studies have evaluated antibody persistence! Concluded that ~50% of persons vaccinated 5 years earlier had bactericidal antibody levels protective against meningococcal disease! Two studies evaluated response after a booster dose at 3 and 5 years after the primary vaccination! At both 3 and 5 years after the first dose, the booster dose elicited substantially higher antibody titers (2-3 times higher) Cost-effectiveness for Adolescent Vaccination Cases averted Dosage No. Range Deaths averted QALY saved No. Range No. Range Cost per QALY saves ($1000) No. Range at 11 yrs 94 (43-165) 11 (5-20) 736 ( ) 256 (84-650) at 15 yrs 115 (51-205) 14 (6-35) 850 ( ) 219 (63-600) 22 (11-40) 1442 ( ) 212 (67-535) at 11 yrs with 184 booster dose at 16 yrs (92-308) 16
5 17 Age years Vaccine Age Primary Series Booster years at age 16 years years at age years years Not needed years Not routinely recommended. May be administered as catch-up for those who have not received a dose after their 16th birthday. Not needed MenACWY-D or MenACWY-CRM 2-23 Months with High-risk Conditions Subgroup have persistent complement deficiencies! travel to or are residents of countries where meningococcal disease is hyperendemic or epidemic! are at risk during a community outbreak attributable to a vaccine serogroup Age of Primary Vaccination Booster Dose MenACWY-CRM at 2, 4, 6, and 12 mo! MenACYW-D at 9 and 12 mo! Hib-MenCY-TT at 2, 4, 6, and mo (not indicated for international travel) Person remains at risk and completed the primary series should receive additional dose of MenACWY 3 years after primary immunization; boosters should be repeated every 5 years thereafter 2-55 Years with High-risk Conditions and Not Previously Vaccinated Subgroup Primary Vaccination have persistent complement deficiencies! have functional or anatomic asplenia! have HIV, if another indication for vaccination exists 2 doses of MenACYW, 8-12 weeks apart Subgroup Primary Vaccination 19 Booster Dose Person remains at risk and completed the primary series at age:! 2 mos- 6 yrs: Should receive additional dose of MenACWY 3 years after primary immunization; boosters should be repeated every 5 years thereafter! 7 yrs: Men ACYW every 5 years after primary immunization 2-55 Years with High-risk Conditions and Not Previously Vaccinated first year college students ages 21 years living in residential housing! travel to or residents of countries where meningococcal disease is hyperendemic or epidemic! of MenACYW are at risk during a community outbreak! are microbiologists routinely exposed to isolates of Neisseria meningitidis 18 Booster Dose Person remains at risk and completed the primary series at age:! 2-6 yrs: Should receive additional dose of MenACWY 3 years after primary immunization; boosters should be repeated every 5 years thereafter! 7 yrs: Men ACYW every 5 years after primary immunization 20
6 National Immunization Survey* National 21 Kansas 100 Percent *Percent of year old adolescents who received 1 MenACWY 2013 CDC, MMWR July 25, 2014;63:625-33, MMWR Aug 30, 2013;62:685-93, MMWR Aug 31, 2012;61:671-67, MMWR Aug 26, 2011;60: , MMWR Aug 20, 2010;59: , MMWR Sept 18, 2009;58: Influenza Update 2014/2015 ACIP Recommendations 23 ACIP meeting June 25, 2014! Grohskoph AL, Olsen SJ, Sololow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, season. MMWR 2014;63:691-7.! Annual influenza vaccination is recommended for all persons aged 6 months and older New and/or Revised Information Vaccine composition! Minor change to egg allergy language! New recommendations regarding use of LAIV and IIV for young children where either is available and appropriate! Dosing 24
7 Vaccine Strain Selection 25 For 2014/2015, recommended the same composition as for the 2013/2014 Northern Hemisphere vaccine! an A/California/7/2009 (H1N1)pdm09-like virus! an A/Texas/50/2012 (H3N2)-like virus! a B/Massachusetts/2/2012-like virus! for quadrivalent vaccines, the above viruses and a B/Brisbane/60/2008-like virus Vaccination of Persons with Severe Egg Allergy 26 Previous language! Persons who report having had reactions to egg involving such symptoms as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, particularly those that occurred immediately or within a short time after egg exposure may receive RIV3, if aged years and there are no contraindications. If RIV3 is not available or the recipient is not within the indicated age range, such persons should be referred by a physician with expertise in the management of allergic conditions for further risk assessment before receipt of vaccine. Vaccination of Persons with Severe Egg Allergy 27 New language! Persons who report having had reactions to egg involving such symptoms as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, particularly those that occurred immediately or within a short time after egg exposure may receive RIV3, if aged years and there are no contraindications. If RIV3 is not available or the recipient is not within the indicated age range, IIV should be administered by a physician with experience in the recognition and management of severe allergic conditions. Use of LAIV and IIV for Healthy Children aged 2-8 years All individuals 6 months of age should receive influenza vaccine. Influenza vaccine should not be delayed to procure a specific vaccine preparation if an appropriate one is already available.! When both LAIV and IIV are available, LAIV should be used for healthy children aged 2 through 8 years who have no contraindications or precautions.! If LAIV is not immediately available, IIV should be used. Vaccination should not be delayed in order to procure LAIV. 28
8 Persons Who Should Not Receive LAIV 29 LAIV should not be administered to! Those aged <2 years or >49 years! Those with contraindications as per the package insert! children aged 2-17 years receiving aspirin! persons who have had allergic reactions to the vaccine or its components! Pregnant women Persons Who Should Not Receive LAIV 30 Immunosuppressed persons! Persons with egg allergy! Children aged 2-4 years who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health-care provider stated that they had wheezing or asthma with the last 12 months! Persons who have taken influenza antiviral medications within the previous 48 hours Precautions for LAIV 31 Asthma in persons aged 5 years! Other chronic medical conditions conferring higher risk of complications due to influenza are precautions to use of LAIV! chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)! per package insert, safety has not been established! Persons who care for severely immunosuppressed persons who require a protective environment! or if given LAIV should avoid contact with such persons for 7 days Dose Considerations Children aged 6 months through 8 years require 2 doses of influenza vaccine administered 4 weeks apart during their first season of vaccination! Because the strains contained in the 2014/2015 vaccine are identical to those in the 2013/2014 vaccine, only one 2014/2015 dose is required for any child 6 months through 8 years who previously received of the 2013/2014 influenza vaccine 32
9 33 Dose Considerations If a child did not receive a dose of the 2013/2014 influenza vaccine or it is unknown if they received that vaccine, then the following alternate approaches for determining the necessary number of doses are acceptable 34 Dose Considerations 1. if the child received a total of at least 2 doses of seasonal influenza vaccine since July 1, 2010 they only need one dose of the 2014/2015 vaccine! 2. 2 or more doses of seasonal influenza vaccine before July 1, 2010 and 1 or more doses of monovalent 2009(H1N1) vaccine! 3. 1 or more doses of seasonal influenza vaccine before July 1, 2010 and 1 or more doses of seasonal influenza vaccine since July 1, 2010 Morbidity and Mortality Weekly Report FIGURE 1. Influenza vaccine dosing algorithm for children aged 6 months through 8 years Advisory Committee on Immunization Practices, United States, influenza season* Did the child receive at least of the seasonal influenza vaccine? Yes No/ Don t know Did the child receive a total of at least 2 doses of seasonal influenza vaccine since July 1, 2010? Yes No/ Don t know 2 doses * For simplicity, this algorithm takes into consideration only doses of seasonal influenza vaccine received since July 1, 2010, to determine the number of doses needed for the season. As an alternative approach in settings where vaccination history from before July 1, 2010, is available, if a child aged 6 months through 8 years is known to have received either 1) at least of seasonal influenza vaccine, or 2) at least two seasonal influenza vaccines during any previous season, and at least of a 2009(H1N1) containing vaccine (i.e., seasonal vaccine since or the monovalent 2009[H1N1] vaccine), then the child needs only for Using this approach, children aged 6 months through 8 years need only of vaccine for if they have received any of the following: 1) at least of seasonal influenza vaccine; or 2) 2 or more doses of seasonal influenza vaccine since July 1, 2010; or 3) 2 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of monovalent 2009(H1N1) vaccine; or 4) 1 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of seasonal influenza vaccine since July 1, Children in this age group for whom one of these conditions is not met require 2 doses for Doses should be administered at least 4 weeks apart. published studies, vaccines containing as much as 0.7 µg/0.5 ml of ovalbumin have been tolerated (27,28); however, a threshold below which no reactions would be expected is not known (27). Among IIVs for which ovalbumin content was disclosed during the through seasons, the reported maximum amounts were 1 µg/0.5 ml dose. Ovalbumin is not directly measured for Flucelvax; it is estimated by calculation from the initial content in the reference virus strains to contain less than 5x10-8 µg of total egg protein per 0.5mL dose, of which ovalbumin is a fraction (Novartis, personal communication, 2013). FluBlok is considered egg-free. However, neither Flucelvax nor FluBlok are licensed for use in children aged <18 years. ACIP recommends the following: 1. Persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, IIV or trivalent recombinant influenza vaccine (RIV3) should be used. RIV3 may be used for persons aged 18 through 49 years who have no other contraindications. However, IIV (egg- or cell-culture based) may also be used, with the following additional safety measures (Figure 2): Vaccine should be administered by a health care provider who is familiar with the potential manifestations of egg allergy; and Vaccine recipients should be observed for 30 minutes for signs of a reaction after administration of each vaccine dose. 2. Persons who report having had reactions to egg involving such symptoms as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, may receive RIV3 if they are aged 18 through 49 years and there are no other contraindications. If RIV3 is not available or the recipient is not within the indicated age range, IIV should be administered by a physician with experience in the recognition and management of severe allergic conditions (Figure 2). 3. Regardless of allergy history, all vaccines should be administered in settings in which personnel and equipment for rapid recognition and treatment of anaphylaxis are available (29). 4. Persons who are able to eat lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic. Egg-allergic persons might tolerate egg in baked products (e.g., bread or cake). Tolerance to egg-containing foods does not exclude the possibility of egg allergy. Egg allergy can be confirmed by a consistent medical history of adverse reactions to eggs and egg-containing foods, plus skin and/or blood testing for immunoglobulin E directed against egg proteins (30). 5. For persons with no known history of exposure to egg, but who are suspected of being egg-allergic on the basis of previously performed allergy testing, consultation with a physician with expertise in the management of allergic conditions should be obtained before vaccination (Figure 2). Alternatively, RIV3 may be administered if the recipient is aged 18 through 49 years. 6. A previous severe allergic reaction to influenza vaccine, regardless of the component suspected of being responsible for the reaction, is a contraindication to future receipt of the vaccine. MMWR / August 15, 2014 / Vol. 63 / No. 32 Pertussis Vaccine
10 Fatal Pertussis in Infants 37 Paddock et al, Clin Infect Dis 2008;47:328-38! Refractory pulmonary hypertension! Hyperleukocytosis Infant Pertussis: Who Was the Source? Other! 25% Grandparent! 8% Sibling! 20% 38 Mother! 32% Father! 15% Bisgard KM, et al. Pediatr Infect Dis J. 2004;23(11): ACIP Meeting June Voted to recommend the routine use of Tdap vaccines in adolescents aged years in place of Td vaccines! Preferred age is years! Adolescents who have received Td but not Tdap are encouraged to receive a single dose of Tdap! ACIP Meeting Oct 2010 Uncertainty about whether someone had recently received a Td vaccine should not rule out receiving Tdap! Tdap can be administered regardless of the interval since the last tetanus or diphtheria containing vaccines 40
11 41 ACIP Meeting Oct 2010! Adults ages 65 years and older who have or who anticipate having close contact with an infant ages less than 12 months (e.g., grandparents, child-care providers, and HCP) and who have not previously received Tdap should receive a single dose of Tdap!! ACIP Meeting June 22, Use of Tdap in Pregnant Women! Women s health care providers should implement a Tdap vaccination program for pregnant women who have not previously received Tdap.! Preferably after 20 weeks gestation! If not administered during pregnancy, Tdap should be administered immediately postpartum! h#p:// 43 ACIP Oct 2012 Recommended that Tdap be given to women during every pregnancy! Optimal timing is between weeks gestation National Immunization Survey* National Kansas Percent *Percent of year old adolescents who received Tdap since age 10 CDC, MMWR July 25, 2014;63:625-33; MMWR Aug 30, 2013;62:685-93; MMWR Aug 31, 2012;61:671-67; MMWR Aug 26, 2011;60: ; MMWR Aug 20, 2010;59: ; MMWR Sept 18, 2009;58:
12 Tdap Coverage Among Adults in years 65 years Total No Infant Contact Infant contact MMWR, Feb 7, 2014;63: HPV Vaccine Coverage For Girls years Percent National Kansas HPV 2 HPV 3 HPV HPV Vaccine Coverage For Boys years National Percent Percent Vaccinated 45 Kansas HPV HPV 3 HPV 48 Questions
13 FIGURE 1. Influenza vaccine dosing algorithm for children aged 6 months through 8 years Advisory Committee on Immunization Practices, United States, influenza season* Did the child receive at least of the seasonal influenza vaccine? Yes No/ Don t know Did the child receive a total of at least 2 doses of seasonal influenza vaccine since July 1, 2010? Yes No/ Don t know 2 doses * For simplicity, this algorithm takes into consideration only doses of seasonal influenza vaccine received since July 1, 2010, to determine the number of doses needed for the season. As an alternative approach in settings where vaccination history from before July 1, 2010, is available, if a child aged 6 months through 8 years is known to have received either 1) at least of seasonal influenza vaccine, or 2) at least two seasonal influenza vaccines during any previous season, and at least of a 2009(H1N1) containing vaccine (i.e., seasonal vaccine since or the monovalent 2009[H1N1] vaccine), then the child needs only for Using this approach, children aged 6 months through 8 years need only of vaccine for if they have received any of the following: 1) at least of seasonal influenza vaccine; or 2) 2 or more doses of seasonal influenza vaccine since July 1, 2010; or 3) 2 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of monovalent 2009(H1N1) vaccine; or 4) 1 or more doses of seasonal influenza vaccine before July 1, 2010, and 1 or more doses of seasonal influenza vaccine since July 1, Children in this age group for whom one of these conditions is not met require 2 doses for Doses should be administered at least 4 weeks apart.
Update ACIP Influenza Vaccination Recommendations for
Update ACIP Influenza Vaccination Recommendations for 2014-15 Lisa Grohskopf, MD, MPH Influenza Division, CDC IAC Webinar 11 September 2014 National Center for Immunization and Respiratory Diseases Influenza
More informationImmunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXIII NUMBER 4 September 2018 CONTAGIOUS COMMENTS Department of Epidemiology Influenza Vaccination Suchitra Rao, MBBS and Jason Child, PharmD New influenza vaccines have arrived. It is important
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationNeedle Facts: Immunization Update Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy
Needle Facts: Immunization Update 2015 Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy Objectives Pharmacists At the conclusion of this program, the pharmacist will be able
More informationTalkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition
Talkin Flu Mid-America Immunization Coalition August 18, 2016 William Atkinson, MD, MPH Immunization Action Coalition Disclosures William Atkinson has worked as a consultant to Merck and as a speaker for
More informationImmunization Update Tamara Sheffield, MD, MPA, MPH
Immunization Update 2015 Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed by Intermountain Healthcare
More informationMA Adult Immunization Coaltion Flu Update September 28, 2016
MA Adult Immunization Coaltion Flu Update September 28, 2016 Susan M. Lett, MD, MPH Medical Director, Immunization Program Division of Epidemiology and Immunization Massachusetts Department of Public Health
More information2017 Vaccination Update
2017 Vaccination Update NATHAN BOONSTRA, MD General Pediatrician, Blank Pediatric Clinic TODAY S OBJECTIVES Review the latest recommendations for immunizations, including HPV Meningococcal vaccines Influenza
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationVACCINE-PREVENTABLE DISEASES (VPDS): CURRENT TRENDS
VACCINE-PREVENTABLE DISEASES (VPDS): CURRENT TRENDS Adult Immunization Conference April 10, 2018 Steve Fleming, EdM stephen.fleming@state.ma.us Presenter Disclosure Information I, Steve Fleming, have been
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationDisclosures. No support One off-label recommendation
Seasonal Influenza John B. Murphy, MD Professor of Medicine and Family Medicine Warren Alpert Medical School of Brown University Executive Vice President for Physician Affairs, Lifespan 8/21/14 Disclosures
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
More informationImmunization Update 2016 Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2016 Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations
More informationImmunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs
More informationDisclosures. Potential conflicts. No off-label use discussion. Safety Review Committee. Data and Safety Monitoring Board
2016 Vaccine Update Clinical Reviews Rochester, Minnesota November 2 and November 16, 2016 Robert M Jacobson, MD, FAAP Medical Director, Mayo Clinic Primary Care Immunization Program Disclosures Potential
More informationHIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS. Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan
HIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan DISCLOSURES No financial or other conflicts to disclose LEARNING OBJECTIVES
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationInfluenza Clinical Bulletin # 3: October 8, 2009 Vaccination Guidelines for Patients for Influenza
The purpose of this document is to provide NYP providers with the most current recommendations regarding influenza vaccination for their patients. It is important to recognize that guidance reflects optimal
More informationMDPH Influenza Update
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Influenza Update 9-27-2017 Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department
More informationRecommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016
Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016 This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended
More information2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
2013 Adult Immunization Update David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Adult Immunization Update Pertussis Vaccine Influenza Vaccine Zoster
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationImmunization Update. William Atkinson, MD, MPH. Immunization Action Coalition
Immunization Update William Atkinson, MD, MPH Immunization Action Coalition Coordinated School Health Conference Lake Ozark, Missouri December 3, 2016 1 Disclosures William Atkinson has no financial relationships
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationWhat You Need to Know About the Flu
Wednesday, August 0, 017 BLUE P FISH E D I A T R I C S www.bluefishmd.com CYPRESS EDITION Biannual Newsletter In This Issue Find Out: Who should receive the flu vaccine? Who should NOT receive the flu
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Immunizations Donald Middleton, MD & Richard Zimmerman,
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationSummary of Recommendations for Adult Immunization (Age 19 years and older) (Page 2 of 5)
Summary of Recommendations for Adult Immunization (Age 19 years and older) (Page 1 of 5) Influenza Inactivated Influenza (IIV*) or ID (intradermally) *includes recombinant influenza (RIV) Live attenuated
More information8/10/17 UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE. Objectives. Background: ACIP. Membership. Focus
UPDATES IN ADOLESCENT AND ADULT IMMUNIZATIONS IN AMBULATORY CARE Laurie L. Duran, MSN, CRNP-Adult Texas Nurse Practitioners 29 th Annual Conference Sep 2017 Objectives 1. Use available resources to interpret
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More information! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted! Traditionally
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationAdult Immunization Update 2015
Adult Immunization Update 2015 Objectives Upon completion of this session, the pharmacist should be able to: Compare and contrast previous versions of the ACIP immunization schedules with the most recent
More informationPreventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.
Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationRecommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017
Caring for Our Children: National Health and Safety Performance Standards H Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 In February 2017, the Recommended Immunization
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationNeedle Facts: Immunization Update 2016
Needle Facts: Immunization Update 2016 Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Disclosure / Conflict of Interest Miranda Wilhelm
More informationACIP Recommendations
ACIP Recommendations Lisa Grohskopf, MD, MPH Influenza Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Influenza Vaccine Summit May
More informationImmunization Update 2013 Across the Lifespan
Immunization Update 2013 Across the Lifespan Andrew Kroger M.D., M.P.H. Medical Officer, Centers for Disease Control and Prevention New York State Association of County Health Officials (NYSACHO) New York
More informationImmunization Update 2017 Peds Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Peds Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Hepatitis B Meningococcal
More informationOverview of Immunizations for People Who Work in Labs
Overview of Immunizations for People Who Work in Labs CLMA/ASCLMS Spring Meeting Little Rock, AR April 5, 2019 Jennifer Dillaha, MD Medical Director, Immunizations Medical Advisor, Health Literacy Arkansas
More informationMandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
More informationImmunizations. Update Immunizations through Time. Learning Objectives. Presenter Disclosure Information. 10:30 11:45am. Immunization Update
10:30 11:45am Immunization Update SPEAKER John Russell, MD Presenter Disclosure Information The following relationships exist related to this presentation: John Russell, MD, serves on Speaker s Bureau
More informationVaccines, Not Just for Babies
Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationAdolescent Immunizations
Adolescent Immunizations Preteen Vaccine Week Webinar January 23, 2008 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Younger Children AND Adolescents Need Immunizations!
More informationImmunization Update: What s New?
Immunization Update: What s New? Joseph A. Bocchini, Jr. MD, FAAP Professor and Chairman Department of Pediatrics Louisiana State University Health Sciences Center Shreveport Red Stick Potpourri LA Chapter-American
More informationNC IMMUNIZATION COALITION FLU THEN AND NOW NC DHHS COMMUNICABLE DISEASE BRANCH ANITA VALIANI, MPH AUGUST 1, 2018
NC IMMUNIZATION COALITION FLU THEN AND NOW NC DHHS COMMUNICABLE DISEASE BRANCH ANITA VALIANI, MPH AUGUST 1, 2018 OBJECTIVES I. 2017-18 Influenza Season Recap of the season nationally Influenza Burden Estimates
More informationInfluenza Prevention Update
Influenza Prevention Update Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur, Merck Discussion off label use of FDA approved vaccines Influenza Prevention Update Seasonal influenza
More informationSlide 1. Slide 2 Disclosure. Slide 3 Learning Objectives
Slide 1 2016 Immunization Update for Pharmacists Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Slide 2 Disclosure Miranda Wilhelm reports:
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More information2017 Immunization Update for Pharmacy Professionals
2017 Immunization Update for Pharmacy Professionals North Suburban Pharmacists of Chicagoland CPE Program May 3, 2017 Lauren B. Angelo, PharmD, MBA Associate Professor Rosalind Franklin University of Medicine
More informationVaccines for infants- What has happened in the last year?
Vaccines for infants- What has happened in the last year? MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Lots has happened and it can be a little confusing Infants used to require
More informationNational Immunization Update
National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have
More informationNational Immunization Update
National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have
More informationSeasonal Influenza. Provider Information Sheet. Infectious Disease Epidemiology Program
August 2007 te: This sheet contains information on seasonal influenza. For information on avian or pandemic influenza, contact the (800-423-1271 or 304-558-5358). What is influenza-like illness (ILI)?
More informationThe Advisory Committee on Immunization
Need-to-know information for the 2016-2017 flu season ACIP now advises against using the LAIV nasal spray. In addition, 2 new vaccines are available and 2 more may soon be approved. Doug Campos-Outcalt,
More informationNothing to disclose. Vaccinations for Adults and Adolescents: An Update. Key Resource
Vaccinations for Adults and Adolescents: An Update Nothing to disclose. Lisa G. Winston, MD Professor of Medicine, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital
More informationImmunization Update 2013
Immunization Update 2013 Andrew Kroger M.D., M.P.H. Centers for Disease Control and Prevention American Academy of Pediatrics Connecticut Chapter December 3, 2013 National Center for Immunization & Respiratory
More informationAdult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Adult Immunization Update 2017 Including Influenza General Best Practice Guidelines for Immunization
More informationObjectives 1. Become familiar with current immunization schedules for children
Sarah Matches, DO, FAAP Assistant Professor UNTHSC, Dept. of Pediatrics Objectives 1. Become familiar with current immunization schedules for children 2. Describe the international progress in reducing
More information7/13/2016. Immunization Update Disclosures. Objectives. No financial disclosures to report
Immunization Update 2016 Courtney A. Robertson, PharmD Clinical Assistant Professor University of Louisiana at Monroe School of Pharmacy Disclosures No financial disclosures to report Objectives Pharmacists
More information9/12/2018. Influenza and Influenza Vaccines. Influenza. Influenza Virus. Highly infectious viral illness. First pandemic in 1580
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Influenza and Influenza Vaccines Adult Track Photographs and images included in this presentation are
More informationNeedle Facts: Immunization Update 2017
Needle Facts: Immunization Update 2017 Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville (SIUE) School of Pharmacy Disclosure and Conflict of Interest Miranda
More informationSummary of Recommendations for Adult Immunization (Age 19 years and older) PAGE 1 OF 5
Summary of Recommendations for Adult Immunization (Age 19 years and older) PAGE 1 OF 5 Influenza Inactivated Influenza vaccine (IIV*) or ID (intradermally) * includes recombinant influenza vaccine (RIV3)
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season October 1 st, 2017 (CDC Disease Week 40) marked the beginning of the 2017 2018 influenza season. Influenza activity is increasing in California. As of November
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity is widely circulating in California. As of week 52 (December 24 30, 2017), the statewide geographic distribution
More informationNeil S. Silverman, MD Center for Fetal Medicine & Women s Ultrasound, LA Clinical Professor, Dept. of Obstetrics and Gynecology Division of
Neil S. Silverman, MD Center for Fetal Medicine & Women s Ultrasound, LA Clinical Professor, Dept. of Obstetrics and Gynecology Division of Maternal-Fetal Medicine David Geffen School of Medicine at UCLA
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More information9/22/2016. Disclosure / Conflict of Interest. Learning Objectives: Pharmacists. Testing Your Knowledge. Learning Objectives: Pharmacy Technicians
Disclosure / Conflict of Interest Needle Facts: Immunization Update 2016 Miranda Wilhelm, PharmD Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Miranda Wilhelm
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More information10/6/2014. INFLUENZA: Why Should We Take The Vaccine? OUTLINE INFLUNZA VIRUS INFLUENZA VIRUS INFLUENZA VIRUS
INFLUENZA: Why Should We Take The Vaccine? Baptist Hospital Baptist Children s Hospital Doctors Hospital J. Milton Gaviria, MD, FACP October 17, 2014 Homestead Hospital Mariners Hospital Baptist Cardiac
More informationQuestions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education
New Jersey Department of Health, Vaccine Preventable Disease Program Questions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education Frequently Asked Questions
More information7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids
7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization
More information2/29/2016. Disclosures. Learning Objectives
Cody Sasek, MPAS, PA C Assistant Professor and Academic Director Physician Assistant Education University of Nebraska Medical Center Omaha, NE Disclosures It is the policy of the University of Nebraska
More informationImmunization Update 2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Donna L. Weaver, RN, MN Nurse Educator Immunization Services Division Connecticut
More informationNovel H1N1 Influenza A Update. William Muth MD 2 Oct 2009
Novel H1N1 Influenza A Update William Muth MD 2 Oct 2009 Novel H1N1 Influenza A Update Epidemiology Treatment Chemoprophylaxis Vaccine Infection Prevention Novel H1N1 Influenza A International Epidemiology
More informationQuestions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education
New Jersey Department of Health (NJDOH), Vaccine Preventable Disease Program Questions and Answers on Immunization Regulations Pertaining to Children Attending School/ Higher Education Frequently Asked
More information16 November 2017 National Immunisation Advisory Committee Recommendations for the 2017/2018 Influenza Vaccination Campaign
16 November 2017 National Immunisation Advisory Committee Recommendations for the 2017/2018 Influenza Vaccination Campaign Please note the National Immunisation Advisory Committee (NIAC) has updated the
More informationPertussis: Clinical Review and Colorado s Epidemic
Pertussis: Clinical Review and Colorado s Epidemic Today s Speakers: Robert Brayden, MD, Professor of Pediatrics, University of Colorado School of Medicine, Children s Hospital Colorado Lisa Miller, MD,
More informationVaccine Preventable Diseases Among Adults
Vaccine Preventable Diseases Among Adults Stephanie Borchardt, MPH, PhD Wisconsin Immunization Program Division of Public Health Wisconsin Department of Health Services November 17, 2016 At a Glance Burden
More informationWhat are the new active vaccine recommendations in the Canadian Immunization Guide?
154 CCDR 17 April 2014 Volume 40-8 https://doi.org/10.14745/ccdr.v40i08a03 1 What are the new active vaccine recommendations in the Canadian Immunization Guide? Warshawsky B 1 and Gemmill I 2 on behalf
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity remains elevated throughout California. As of 2018 week 9 (February 25 March 3, 2018), the statewide geographic
More information